The short answer
A network meta-analysis compares treatments that were never tested against each other by linking them through comparators they share, usually placebo. It produces indirect estimates, and rests on the assumption that the trials being linked are similar enough to connect.
Key facts
- Purpose
- Compare without a head-to-head
- Method
- Link trials through shared comparators
- Key assumption
- Transitivity (trials are comparable)
- Threatened by
- Differing populations, durations, endpoints
- Weaker than
- A direct randomised comparison
- Stronger than
- Informal cross-trial comparison
The problem it solves
Most treatments are never tested directly against each other, because head-to-head trials are expensive and commercially risky. Yet the question of which works better is what prescribers and payers need answered. Network meta-analysis extracts an answer from trials that already exist rather than requiring a new one.
How the linking works
If A was tested against placebo and B was tested against placebo, the difference between A and B can be estimated through their shared comparator. Extend that across many treatments and comparators and you get a network (hence the name) in which most pairs are connected by some path even where no direct edge exists.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The assumption everything rests on
Transitivity: that the trials being linked are similar enough that the comparison means something. If the trials of A enrolled healthier participants, ran shorter, or measured a different endpoint than the trials of B, the indirect comparison inherits those differences and attributes them to the treatments.
Why it is nonetheless better than what people do informally
Reading two trial results side by side and concluding one drug beats another is an indirect comparison too, just an undisciplined one, with no adjustment and no acknowledgement of uncertainty. A network meta-analysis does the same thing explicitly, propagates uncertainty into the estimate, and can be examined for whether the assumption holds.
Where it sits in the hierarchy
Below a direct randomised head-to-head, which is why REDEFINE 4 comparing CagriSema against tirzepatide, and TRIUMPH-5 comparing retatrutide against tirzepatide, carry weight that no network analysis can substitute for. Above informal comparison. It is a legitimate method used where the better evidence does not exist.
How to read one critically
Look at what the network actually connects and how. A comparison resting on one small trial as its only bridge is fragile regardless of how much data sits elsewhere in the network. Look at whether populations and durations across the linked trials are really comparable, and whether the authors examined that rather than asserting it.
Quick reference
| Head-to-head | Network meta-analysis | Informal comparison | |
|---|---|---|---|
| Randomised between arms | Yes | Within trials only | No |
| Uncertainty propagated | Yes | Yes | No |
| Assumption required | Minimal | Transitivity | Unstated |
Frequently asked questions
How can a network meta-analysis compare untested pairs?
By linking them through shared comparators. If both were tested against placebo, the difference can be estimated through that common arm.
What is transitivity?
The assumption that the trials being linked are similar enough for the comparison to mean something. Differing populations or durations undermine it.
Is it as good as a head-to-head?
No. It sits below a direct randomised comparison, though above the informal side-by-side reading people do without it.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedSabatella L et al., Comparative efficacy of metabolic/bariatric surgery versus GLP-1 receptor agonists: a network meta-analysis of randomized controlled trials. Obesity 2026 (PMID 41326176)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · CagriSema compared to tirzepatide (NCT06131437)clinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383)clinicaltrials.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- A Second Entrant to Tirzepatide's MechanismVK2735 is a GIP/GLP-1 dual agonist - the same receptor pair as tirzepatide. Its Phase 2 VENTURE study ran 13 weeks, too short to compare with 72-week data.
- A GLP-1/Glucagon Dual Aimed at the LiverPemvidutide pairs GLP-1 with glucagon receptor agonism and was studied for 24 weeks in metabolic dysfunction-associated steatotic liver disease.
- An Amylin Analogue Built to Stand AlonePetrelintide is described as a potent, stable, long-acting human amylin analogue - engineered by Zealand Pharma with Boehringer Ingelheim.
- The Amyloid Problem at the Centre of Amylin DesignHuman amylin forms amyloid fibrils. Every amylin medicine is a solution to that, and the two available solutions are instructively different.
- The Class's Defining Safety PropertyGLP-1 amplifies insulin secretion only when glucose is already elevated. Below that threshold the signal does almost nothing - which is the whole point.